2024-10-06 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-saving medicines for serious diseases.

**Performance Analysis:**

1. **Relative Performance:**
    * REGN's cumulative return is 93.29%, while the S&P 500 (VOO) has returned 131.01%. 
    * The current return difference is -37.72%, with a relative divergence of 37.41%. This indicates that REGN has underperformed the S&P 500 in the past, currently lagging behind by 37.72%. 

2. **Recent Price Movement:**
    * Closing price: 1014.59
    * 5-day moving average: 1043.1
    * 20-day moving average: 1100.79
    * 60-day moving average: 1116.55

    This suggests a downward trend in the stock price, as the price is below all three moving averages.

3. **Technical Indicators:**
    * RSI: 22.25 (oversold)
    * PPO: -0.93 (weak momentum)
    * Delta_Previous_Relative_Divergence: -25.76 (short-term downtrend)
    * Expected Return: 0.0% (no expected return compared to S&P 500 over the next 5 years)

    These indicators collectively signal weak momentum and potential oversold conditions in the stock. 

4. **Recent Earnings & Outlook:**

| Date       | EPS     | Revenue  |
|------------|---------|----------|
| 2024-08-01 | 13.25   | 3.55 B$  | 
| 2024-05-02 | 6.7    | 3.15 B$  | 
| 2023-11-02 | 9.48    | 3.36 B$  |
| 2023-08-03 | 9.05    | 3.16 B$  |
| 2024-08-01 | 9.05    | 3.16 B$  |

The latest earnings report for Q2 2024 revealed an EPS of 13.25 and revenue of $3.55 billion. This surpassed analyst expectations and demonstrated continued revenue growth. However, it's important to note that the earnings were boosted by a one-time gain from the sale of a company's subsidiary. 

5. **News and Current Issues:**
    * Recent news regarding REGN focuses on their potential for significant growth in the upcoming years due to the success of their blockbuster drug Eylea and pipeline of promising drugs in development. 
    * Analyst opinions are generally positive, with many analysts predicting a long-term upward trend for REGN's stock price.
    * FINBOLD reports that Regeneron is well-positioned to benefit from the growth of the global ophthalmology market. 

**Overall Analysis:**

* REGN has lagged behind the S&P 500 in the past but has shown signs of strong earnings growth.
* The company's pipeline of new drugs presents significant growth potential.
* Technical indicators suggest weak momentum and potential oversold conditions, but the latest earnings report might trigger a positive change in sentiment.
* Overall, REGN presents a mixed picture with opportunities and potential risks. Investors should carefully consider their own risk tolerance and investment goals before making any decisions. 
